Therapeutic Strategies for the Management of HCV/HIV co-

HCV/HIV 合并治疗的治疗策略

• 批准号: 7299927
• 负责人: Shyamasundaran Kottilil
• 金额: --
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7299927
• 关键词: Therapeutic; Strategies; Management; HCV; HIV

Recent advances in the treatment and monitoring of HIV-1 infection have substantially diminished HIV-associated illness and mortality; however the management of HIV-infected patients has become increasingly complex. We are conducting studies that: (1) define the role of Hepatitis C viral response to pegylated interferon-based therapy (2) evaluate novel therapeutic strategies in the management of Hepatitis C virus among HIV co-infected individuals, and (3) develop novel genomic and proteomic markers that predict Hepatitis C viral response to existing and newer therapies. Analyses of the kinetics of the viral response to Hepatitis C therapy in Hepatitis C/HIV co-infected individuals suggest that it may be possible to predict long term response to anti-Hepatitis C therapy based on the initial response of the level of Hepatitis C virus in the plasma. Using combination therapy of pegylated interferon together with ribavirin in these subjects, we are determining whether genomic and proteomic markers can predict response to therapy prior to initiation of treatment. Another clinical trial will determine whether more frequent doses of pegylated interferon in combination with ribavirin can enhance the viral kinetic response to Hepatitis C therapy in persons with Hepatitis C infection and HIV infection. A new clinical trial using albumin-conjugated interferon alpha (Albuferon) to treat Hepatitis C among HIV infected patients will begin enrollment later this year.

HIV-1感染的治疗和监测的最新进展显着降低了与HIV相关的疾病和死亡率。但是，感染HIV的患者的管理变得越来越复杂。我们正在进行研究：（1）定义丙型肝炎基于干扰素的疗法的病毒反应（2）评估HIV共同感染的个体中丙型肝炎病毒的新型治疗策略，以及（3）预测新型基因组和蛋白质组学标记，以预测对现有和新型肝炎病毒性响应的作用。对丙型肝炎C/HIV共感染的个体对丙型肝炎治疗的动力学的分析表明，基于血浆中丙型肝炎病毒水平的初步反应，可以预测对抗肝炎治疗的长期反应。在这些受试者中，使用叶甲状干扰素与利巴韦林的联合治疗，我们确定基因组和蛋白质组学标记是否可以在开始治疗之前预测对治疗的反应。另一项临床试验将确定与利巴韦林结合使用的频繁剂量的卵脂干扰素是否可以增强丙型肝炎感染和HIV感染患者对丙型肝炎治疗的病毒动力学反应。一项新的临床试验，使用白蛋白偶联的干扰素α（Albuferon）治疗HIV感染患者中的丙型肝炎，将于今年晚些时候开始入学。